Company / Gross Profit
Sunshine Biopharma Inc. Gross Profit History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$10.7M
FY2025
5-year range
$45.6K / $10.7M
FY2021-FY2025
Trend
+27.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit has increased for 6 consecutive years, from $0 in FY2019 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +302.7%.
Improved from $2M to $11M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +358.6%
- 5-Year CAGR
- +302.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s gross profit has grown for 5 consecutive years.
- 5-year CAGR of +302.7%, indicating consistent growth.
- In FY2025, gross profit increased 27.9% year-over-year.
- Lowest gross profit in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.7M | +27.9% |
| FY2024 | $8.3M | +391.5% |
| FY2023 | $1.7M | +1434.0% |
| FY2022 | $110.6K | +142.7% |
| FY2021 | $45.6K | +352.4% |
| FY2020 | $10.1K | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026